ProMIS Neurosciences Inc PMN

PMN - Trial of New Alzheimer's Drug Slated for Early 2023

[azzymaa]

https://www.streetwisereports.com/article/2022/07/01/trial-of-new-alzheimers-drug-slated-for-early-2023.html

ProMIS Neurosciences Inc.'s (PMN:TSX; ARFXF:OTCQB) lead therapeutic candidate for Alzheimer's disease, PMN310, will be evaluated in a Phase 1b clinical trial in early 2023, Argus Research analyst Steve Silver reported in a June 27 report. PMN310 is a monoclonal antibody that binds with high affinity and selectivity to toxic oligomers of amyloid-beta, a recognized root cause of Alzheimer's disease.

"We estimate that more than 100 candidates for Alzheimer's disease are currently in the clinic and view PMN310 as potentially representing a best-in-class opportunity," Silver wrote.

[BottomBroker]

Paid promotion. 

[retiredcop]

Quite often these paid promotions are worth while paying attention to    I see them as the companies ability to pass on specific information that they as a company are prevented from giving out ...takes liability away if a third party makes specific claim...similar to me saying that something will happen on a certain date...if it doesn't then it just another worthless claim we hear

[BottomBroker]

I'm not saying it's unworthy of attention, I'm just pointing out that this story was not written from a unbiased point of view.

[bball67]

Agree that the initiation of coverage report of April 18, 2022 may have been paid for. It looks like he has made additional comments including the two paragraph extremely positive comment on July 1, 2022. He appears to be a senior analyst with a significant resume. Don't believe the additional short comments are paid for. It is possible he has a strong conviction about the Company and stock